30 May 2019


Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, announces that its Annual General Meeting ("AGM") will be held at 10am on 24 June 2019 at the offices of Liberum at Ropemaker Place, 25 Ropemaker Street, London EC2Y 9LY.

Futura's annual report and accounts for the year ended 31 December 2018 (the "Annual Report") is available to shareholders as an electronic communication pursuant to the Companies Act 2006 and is now available at the Company's website www.futuramedical.com, along with the notice of AGM.

Shareholders who would like to attend the AGM are invited to contact Optimum on +44 (0)203 950 9144 or email futuramedical@optimumcomms.com

 

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670

Liberum (Nominated Adviser and Broker)
Bidhi Bhoma
Euan Brown
Kane Collings
Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144

 

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com